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Erythropoietin receptor (EpoR) has been reported to be overexpressed in tumours and has raised safety concerns regarding the use
of erythropoiesis-stimulating agents (ESAs) to treat anaemia in cancer patients. To investigate the potential for EpoR to be
overexpressed in tumours, we have evaluated human tumours for amplification of the EPOR locus, levels of EPOR transcripts, and
expression of surface EpoR protein. Gene amplification analysis of 1083 solid tumours found that amplification of the EPOR locus was
rare with frequencies similar to other non-oncogenes. EPOR transcript levels in tumours and tumour cell lines were low in
comparison with bone marrow and were equivalent to, or lower than, levels in normal tissues of tumour origin. Although EpoR
mRNA was detected in some tumour lines, no EpoR could be detected on the cell surface using
125I-Epo binding studies. This may be
due to the lack of EpoR protein expression or lack of cell-surface-trafficking factors, such as Jak2. Taken together, we have found no
evidence that EpoR is overexpressed in tumours or gets to the surface of tumour cells. This suggests that there is no selective
advantage for tumours to overexpress EpoR and questions the functional relevance of EpoR gene transcription in tumours.
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Erythropoiesis-stimulating agents (ESAs), epoetin-a, epoetin-b,
and darbepoetin-a, regulate erythropoiesis by binding and
activating the erythropoietin receptor (EpoR) on the surface of
erythropoietic precursor cells, stimulating their survival, prolifera-
tion, and differentiation into mature red blood cells. Recently, off-
label investigational clinical trials that aimed to prevent anaemia in
breast and head and neck cancer patients undergoing chemother-
apy and radiotherapy, respectively, reported a decrease in
locoregional progression-free survival and overall survival in
ESA-treated patients (Henke et al, 2003; Leyland-Jones et al, 2005).
These findings have led to speculation that administration of ESAs
to cancer patients may promote tumour growth through stimulat-
ing EpoR expressed on tumours. This hypothesis appeared to be
supported by the literature, as some investigators have reported
that tumour samples and cell lines transcribe the EPOR gene at
high levels, that 90–100% of primary human tumours overexpress
EpoR protein, and that recombinant human Epo (rHuEpo)
induced proliferative, survival and migration effects on tumour
cell lines (reviewed by Osterborg et al, 2007; Sinclair et al, 2007). In
contrast, most clinical studies have found no increase in tumour
progression or decrease in survival when ESAs are administered to
cancer patients (Bohlius et al, 2006). Furthermore, many studies
have found tumour cell lines are unresponsive to ESAs, including
proliferation and survival of tumour cell lines in vitro (Berdel et al,
1991; Mundt et al, 1992; Rosti et al, 1993; Selzer et al, 2000;
Westphal et al, 2002), and, of most physiological relevance, tumour
growth in vivo (Silver and Piver, 1999; Mittelman et al, 2001;
Stuben et al, 2001, 2003; Thews et al, 2001; Golab et al, 2002; Pinel
et al, 2004; Sigounas et al, 2004; Ning et al, 2005). Thus, there is
conflicting evidence for the role of EpoR in tumour growth.
Concerns have been raised about the lack of specificity of
antibodies used by many studies to detect EpoR. Most studies used
anti-EpoR peptide polyclonal antibodies (C-20; Santa Cruz
Biotechnology, Santa Cruz, CA, USA) in immunoblotting and/or
immunohistochemistry (IHC) experiments (Elliott et al, 2006). We
and others have found that polyclonal antibodies C-20 detected a
66-kDa protein that was substantially larger than EpoR (59kDa)
and was identified to be heat-shock protein HSP70 (Elliott et al,
2006; Brown et al, 2007; Ragione et al, 2007). Owing to cross-
reactivity with non-EpoR proteins (e.g., HSP70), C-20 was found
unsuitable for IHC (Elliott et al, 2006; Brown et al, 2007). In
addition, other anti-EpoR antibodies have been found to be
nonspecific and insensitive and therefore inappropriate for EpoR
detection (Della Ragione et al, 2007; Kirkeby et al, 2007; Laugsch
et al, 2008; Sturiale et al, 2007).
Since the findings and conclusions from studies that used C-20
and other anti-EpoR antibodies to detect EpoR are inconclusive,
we performed an extensive investigation of the potential for EpoR
to be overexpressed in tumour cells through antibody-independent
approaches.
MATERIALS AND METHODS
Cell lines and patient tissue samples
Human cell lines analysed were UT7/Epo (Epo-dependent mega-
karyoblastic leukaemia); MCF-7 (breast carcinoma); HeLa (cervical
carcinoma); SHSY-5Y (neuroblastoma); CAKI-1, CAKI-2, 769P,
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sA704, A498, SW-156, SK-NEP-1 (renal carcinomas); HT29, LS174T
(colon carcinomas); and A549 (lung carcinoma). Tumour samples
for representational oligonucleotide microarray analysis (ROMA)
and quantitative PCR (Q-PCR) analysis were obtained from
Cooperative Human Tissue Network (NCI Cancer Diagnosis
Program), Duke University, University of Michigan, Asterand
Inc. (Detroit, MI, USA), Cytomyx Inc. (Lexington, MA, USA),
Genomics Collaborative (Cambridge, MA, USA), and as previously
described (van der Horst et al, 2005). RNAs from paired normal
and cancerous colon and lung tissue were from Ardais Corp.
(Lexington, MA, USA). Other non-paired tissue mRNAs were
obtained from Stratagene (La Jolla, CA, USA), Clontech (Moun-
tainview, CA, USA), Asterand Inc., Ardais Corp., and Genpak Ltd
(Brighton, UK).
Genomic amplification
DNA for ROMA, comparative genomic hybridisation (CGH) and
Q-PCR was isolated from snap-frozen tumour samples using a
proteinase K method. Representational oligonucleotide microarray
analysis was performed as previously described (Lucito et al, 2003;
van der Horst et al, 2005), and CGH was performed as previously
described (Pei et al, 2002). Data were normalised using a modified
global loss algorithm (Smyth and Speed, 2003) (data not shown),
and amplicon boundaries were determined using the GLAD
algorithm (Hupe et al, 2004) and assembled into a database (data
on file at Amgen Inc.).
Quantitative PCR analysis of the EPOR locus was performed on
DNA from 68 primary breast tumours in multiplex reactions with
one of two sets of EPOR-specific primers and probes. Primer/probe
set A amplified an EPOR fragment within exon 3 (Figure 1):
forward primer, 50-CTTCGTGCCCCTAGAGTTGC-30; reverse pri-
mer, 50-TGATGTGGATGACACGGTGAT-30; and probe, 50-TCACA
GCAGCCTCCGGCGCT-30. Primer/probe set C amplified an EPOR
fragment within exon 8 that encodes the epitope for the M-20 anti-
EpoR antibody (Figure 1): forward primer, 50-TGCCAGCTTTGAG
TACACTATCCT-30; reverse primer, 50-GCTCAGGGCACAGTGTC
CAT-30; and probe, 50-CCCAGCTCCCAGCTCTTGCGTC-30. Probes
were labelled with 6-carboxyfluorescein (FAM) at the 50 end and 6-
carboxytetramethylrhodamine (TAMRA) at the 30 end. A primer/
probe set specific for a relatively invariant region of chromosome
6p22.2 (data on file at Amgen Inc.) was included in each multiplex
reaction, as a non-amplified control: forward primer, 50-GGTCTCT
ATTTGCACTTGGCTGAT-30; reverse primer, 50-TTTTCATTGTT
GACCAAGCTAGACA-30; and probe, 50-TAGGGCATACTGCCTG
CATATTTCCTGCT-30 labelled with VIC at the 50 end and TAMRA
at the 30 end. PCR products were quantified from standard curves
generated with each primer/probe set using normal human
genomic DNA (Novagen, Madison, WI, USA). Each 10ml Q-PCR
mixture contained 5ml2   PCR master mix (Eurogentec, San
Diego, CA, USA), 150nM each primer and probe, and 15–20ng
genomic DNA. DNA amplification was performed using the ABI
7900 (Applied Biosystems, Foster City, CA, USA): denaturation at
951C for 10min, followed by 40 cycles of 15s at 951C and 1min at
601C. Reactions were performed in duplicate and repeated. Data
were analysed using SDS software (Applied Biosystems). The
relative copy number of EPOR using each primer/probe set is the
ratio of the copy number at the EPOR locus to the copy number at
the control locus; the mean relative copy number is presented.
Quantitative RT-PCR
For laser-dissected tumour and stroma RNA, sections were cut and
placed directly into extraction buffer from Picopure RNA Isolation
kit (sunnythanol (2min), Accustain (30s), dH2O (1min), 75%
EtOH, 95% EtOH, 100% Evale; Arcturus/Molecular Devices,
Sunnyvale, CA, USA) or onto glass slides, then into a slide box
on dry ice. Sections were stained as follows: treated with 75% EtOH
( 2), dipped in xylene, and then air-dried. Laser dissection was
performed on a Pixcell IIe System and RNA was extracted using
PicoPure Isolation kit (Arcturus/Molecular Devices), according to
the manufacturer’s instructions. RNA was quantified using the
Beckman DU640 Spectrophotometer at the following wavelengths:
260, 280, and 320nm.
RNA was isolated from cells and tissues using the Absolutely
RNA miniprep kit (Stratagene), treated with DNase I (Roche
Biochemical, Indianapolis, In, USA), and cDNA synthesised using
SuperScript II (Invitrogen, Carlsbad, CA, USA). Quantitative RT-
PCR was performed using three sets of EPOR-specific primers and
probes to amplify fragments within exons 3 (primer/probe set A),
6/7 (primer/probe set B), and 8 (primer/probe set C) (Figure 1).
EPOR was amplified from exons 3 and 8 using primer/probe sets A
and C, and from exon 6/7 using primer/probe set B: forward
primer, 50-ACCGCCGGGCTCTGAA-30; reverse primer, 50-TTCAA
ACTCGCTCTCTGGGC-30; and probe, 50-AGAAGATCTGGCCTGG
CATCCCG-30. Human cyclophilin was amplified using forward
primer, 50-TGCTGGACCCATCACAAATG-30; reverse primer, 50-TG
CCATCCAACCACTCAGTC-30; and probe, 50-TTCCCAGTTTTT
CATCTGCACTGCCA-30. Probes were labelled with FAM (50) and
TAMRA (30). PCR mixtures contained 50ng cDNA, TaqMan
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Figure 1 Genomic organisation of the EPOR locus showing alternatively spliced transcripts and location of primers and probes. Light grey boxes represent
coding regions of exons 1–8, open boxes represent untranslated 50 and 30 regions, and black boxes represent the transmembrane coding sequences. The
three major EPOR transcripts are shown with dashed lines representing normal splicing sites. The hatched boxes represent intronic regions contained in
some alternatively spliced forms. Primer/probe sets A, B, C, and D were designed to amplify EPOR fragments within exons 3, 6–7, 8, and 5–8, respectively.
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sUniversal PCR Master Mix (Applied Biosystems), 450nM primers,
and 200nM probe. An RNA control was included to confirm that
samples were not contaminated with genomic DNA. The
amplification programme was as follows: denaturation at 951C
for 10min, followed by 40 cycles of 951C for 15s and 601C for
1min (ABI PRISM 7700 and PRISM 7900HT Sequence Detection
Systems; Applied Biosystems). Levels of EPOR transcripts were
normalised to cyclophilin. For brain samples and head and neck
laser-dissected samples, cDNA was synthesised using Qiagen’s
OmniScript Reverse Transcriptase kit (Qiagen, Valencia, CA,
USA), using 1mM oligo dT (Invitrogen), 0.5Uml
 1 RNase inhibitor
(Roche Biochemical), 50ng RNA, and 500mM dNTP in a 20ml
reaction. Equal amount (50ng) of the DNase-treated RNA was
used as a negative RT control, and quantitative RT-PCR was
performed using Fast Start SYBR Green PCR Master Mix,
according to the manufacturer’s instructions (Roche Biochemical),
using 0.5mM of forward and reverse primers. Lightcycler 1.5
(Roche Biochemical) parameters were as follows: EpoR, 10min at
951C, then 45 cycles of 15s at 951C, 5s at 621C, 20s at 721C, 901C
for 2s with a reading at the end of the 2s hold time. For human
cyclophilin primers, parameters were as follows: 10min at 951C
and 45 cycles of 15s at 951C, 5s at 671C, 20s at 721C and 2s at 851C
with a reading at the end of the 2s hold time. Lightcycler Detection
software (versions 4.0) was used to analyse and graph the data.
Primer set D (Figure 1) was EpoR 50-CGTATGGCTGAGCCGA
GCTT-30 (exon 5) and 50-CAGCCATCATTCTGGTACAGC-30 (exon
8). Human cyclophilin primers were 50-AGACGCCACCGCCGAG
GAA-30 (exon 1) and 50-TGCCAGGACCCGTATGCTTTAGGA-30
(exon 4).
Expression microarray analysis
Standard cRNA labelling and array processing were conducted
according to the Affymetrix manual (Affymetrix, Santa Clara, CA,
USA). First-strand synthesis used 5mg total RNA, 10pmol T7-
(dT)24 primer, and Superscript II (Invitrogen). Double-stranded
cRNA was purified using the MinElute Reaction Cleanup kit
(Qiagen). Biotinylated cRNA was synthesised using the Bioarray
High Yield RNA Transcript Labeling kit (Enzo Diagnostics,
Farmingdale, NY, USA) for 6h at 371C and purified using the
RNeasy Mini kit (Qiagen). The cRNA was hybridised to the
Affymetrix Human Genome U133 Plus 2.0 array containing five
unique EPOR probe sets: 209962_AT, 209963_S_AT, 215054_AT,
37986_AT, and 396_F_AT, each identifying different subregions
within EPOR exon 8. The arrays were washed using the
EukGE_WS2v4_450 protocol on a GeneChip Fluidic Station 450
and scanned using the Affymetrix GeneChip Scanner 3000. Raw
signal intensities that met the recommended quality criteria were
imported into the gene expression analysis system, Rosetta
Resolver 5.0 (Rosetta Bio-software, Seattle, WA, USA; http://
www.rosettabio.com/tech/default.htm). System processing, includ-
ing normalisation, consisted of algorithms using an error-
modelling approach (Rajagopalan, 2003).
A conventional two-way analysis of variance (ANOVA) was
performed to determine if EPOR was differentially expressed in
tumour vs normal tissues. Normalised intensity values were log
transformed to achieve homoscedacity and used for the ANOVA
calculations. An ANOVA calculation was performed for each tissue
type with disease state and probe set as the two factors. If a
difference was found, a post hoc comparison using the Dunn–
Sidak test was performed. Statistical calculations were made using
Matlab version 6.5.1 (Mathworks Inc., Natick, MA, USA).
Western blot analysis
Cell lysates and immunoblots were prepared as described
previously (Elliott et al, 2006). Membranes were blocked with 5%
milk in TBS containing 0.05% Tween-20, and incubated with
1:1000 dilution anti-Janus kinase 2 (Jak2) antibody (Cell Signaling
Technologies, Danvers, MA, USA) for 2h at room temperature.
The secondary antibody was anti-rabbit IgG conjugated to
horseradish peroxidase (Amersham Biosciences, Piscataway, NJ,
USA). ECL-Plus (Amersham Biosciences) was used for detection.
Blots were stripped and reprobed with 0.25mgml
 1 anti-cyclophi-
lin B (Abcam, Cambridge, MA, USA) as a loading control.
Epo-binding assays
Recombinant human Epo-binding studies were performed as
previously described (Elliott et al, 1997) with some modifications.
Cells were grown to confluency, dissociated with Versene (EDTA/
EGTA), centrifuged, washed, and resuspended in binding buffer
(RPMI, 1% BSA, 0.1% sodium azide, 50mM HEPES, 10mgml
 1
cytochalasin B), and 1 10
6 cells in 80ml were incubated with
133pM
125I-rHuEpo (specific activity, 2500Cimmol
 1), with or
without a 1500-fold excess (200nM) unlabelled rHuEpo, for 2.5h at
371C. Reactions were quenched with 700ml ice-cold PBS/0.5% BSA,
and then centrifuged at 5000g. Surface-bound
125I-rHuEpo was
determined using a Packard Cobra II Auto Gamma Counter
(Perkin-Elmer, Boston, MA, USA) and specific binding calculated
as the difference in
125I-rHuEpo binding in the presence and
absence of excess rHuEpo. For UT7/Epo Scatchard analysis,
varying amounts of cold ligand (10pg to 5ng) in 40ml binding
buffer were added to 10ml
125I-rHuEpo and 50ml5 10
5 UT7/Epo
cells. Each reaction was performed in duplicate. Reaction tubes
were incubated at 371C for 1.5–2h. Cell-bound and free
125I-
rHuEpo were separated through 100% dibutyl phthalate oil in a
fixed angle horizontal rotor at 12000g for 2min at room
temperature. The tubes were frozen in dry ice, the oil phase
containing cell-bound
125I-rHuEpo was extracted, and the amount
of
125I-rHuEpo was determined by scintillation counting. Non-
specific binding was determined by adding a 300-fold excess of
cold rHuEpo to the reaction mix. Scatchard analyses were
performed using Microsoft Excel.
RESULTS
Genomic amplification of EPOR
Representational oligonucleotide microarray analysis and CGH
data from 1083 tumour samples from 15 different tumour types
were analysed for amplification of the EPOR locus. Amplification
of EPOR in amplicons o10Mb was identified in less than 0.7% of
tumours (n¼8) and was similar to the frequency of amplification
of other established non-oncogenic loci such as glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), b-actin (ACTB), and b-
glucuronidase (GUSB) (Figure 2A). None of the tumours with
amplified EPOR contained EPOR in amplicons o1Mb. Oncogenic
loci cyclin D1 (CCND1), HER2, and EGFR were amplified in 3.5–
6.7% of tumours and frequently contained amplicons o1Mb
(Figure 2A). Copy numbers of oncogenic loci were increased 49-
fold in some tumours (Figure 2B). In contrast, the copy number of
EPOR was increased to a maximum of 2–3-fold, concordant with
other non-oncogenic loci (Figure 2B).
To further analyse the frequency of EPOR amplification, Q-PCR
was performed on genomic DNA isolated from 68 primary breast
tumours. Copy numbers of EPOR were between 0.5 and 1.5 in all
tumour samples, except one tumour with a copy gain and one with a
copy deletion (Figure 2C). Both EPOR primer sets yielded
concordant results. Taken together, these results demonstrated that
the EPOR locus was rarely amplified in primary human tumours.
EPOR transcripts in tumours and tumour cell lines
To investigate EPOR overexpression through mechanisms other
than genomic amplification, levels of EPOR transcripts in tumours
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sand cell lines were compared with levels in normal tissues of
tumour origin. Analysis of 24 normal tissues showed that EPOR
was transcribed at high levels in bone marrow, medium levels in
adrenal, and low levels in all other tissues (Figure 3A). Compara-
tive analysis of EPOR transcription in tumour vs non-tumour
tissues determined that transcript levels in kidney, stomach, colon,
and lung tumours and cell lines were lower than those found in
corresponding normal tissues (Figure 3B). Levels of EPOR
transcripts were also not elevated in brain tumours relative to
normal brain (Figure 3C), colon and lung adenocarcinomas
relative to patient-matched normal tissue (Figure 3D), and laser-
dissected tumour epithelia from head and neck tumours relative to
stroma (samples collected from three different regions from each
tumour A–C, Figure 3E).
Levels of EPOR transcripts were further examined in microarray
analyses of 121 tumour and 170 normal tissues. For each of the five
probe sets for EPOR on the HG-U133 Plus 2.0 array, levels of EPOR
transcripts in tumours were not significantly elevated above levels
found in the normal tissue counterpart (Figure 4; data not shown).
Interestingly, a statistically significant (Po0.05) decrease in levels
of EPOR transcripts in kidney tumours, lung squamous cell
carcinoma, lymphomas, and prostate adenocarcinoma relative to
normal tissues was identified (Figure 4). This result was confirmed
with five different probe sets. These data demonstrate that EPOR
transcription is not elevated in tumour samples or cell lines
compared with EPOR transcript levels in the normal, non-tumour
counterpart.
EPOR transcript levels and surface expression in tumour
cell lines
Since EPOR transcripts were detected in tumour cells, albeit at low
levels, we investigated the association between transcript levels and
expression of EpoR at the cell surface. The particular cell lines used
in this study were selected because of reports that they responded
to Epo. The six cell lines included megakaryoblastic leukaemia line
UT7/Epo cells (known to be Epo responsive; Laugsch et al, 2008)
as a positive control; a renal carcinoma line 769P (with extremely
low levels of EpoR mRNA) (Elliott et al, 2006) as a negative
control; and four cell lines in which rHuEpo has been reported to
induce an in vitro response: breast carcinoma line MCF-7 (Acs
et al, 2001), cervical carcinoma line HeLa (Acs et al, 2003; Pajonk
et al, 2004), renal carcinoma line CAKI-2 (Westenfelder and
Baranowski, 2000), and neuroblastoma line SHSY-5Y (Um et al,
2007). Relatively high levels of EPOR transcripts were observed in
UT7/Epo cells, very low levels in MCF-7, HeLa, SHSY-5Y, and
CAKI-2 cells, and negligible levels in 769P cells (Figure 5A). While
UT7/Epo cells bound high levels, none of the solid tumour cell
lines bound detectable levels above background of
125I-rHuEpo,
(Figure 5B). Scatchard analysis demonstrated that UT7/Epo cells
expressed B11700 cell-surface receptors per cell with a binding
affinity of 68pM (Figure 5C). In contrast, 32D cells expressing
murine EpoR expressed relatively low levels of cell-surface
receptors (0.58±0.10% total c.p.m.; B760 receptors per cell; data
not shown), demonstrating the assay was sensitive. These data
indicate that synthesis of EpoR mRNA in solid tumour cell lines
does not predict surface expression; EpoR protein may not be
synthesised in these solid tumour cell lines and/or may be trapped
in the cytoplasm and may not be trafficked to the surface of
the cell.
Janus kinase 2 is required for surface expression of EpoR in
haematopoietic cells (Huang et al, 2001). Variable levels of Jak2
expression were observed in cell lines (Figure 5D), and lack of Jak2
in some may account for, in part, lack of surface EpoR. However,
other cell lines (e.g., CAKI-2) expressed Jak2 protein but still no
surface expression was observed (Figure 5B). These data suggest
that if EpoR protein is synthesised in these cells, it does not get to
the surface of tumour cell lines at detectable levels due to potential
limiting surface-trafficking factors, such as Jak2.
DISCUSSION
Although ESAs have been used safely for numerous years, results
from several recent off-label, investigational clinical trials have
raised concerns that ESAs may have direct tumour-stimulating
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Figure 2 Erythropoietin receptor genomic amplification in tumour
samples. Quantitative genomic microarray analysis was performed on 1083
tumours from 15 different tumour types. (A) Per cent of tumours
demonstrating genomic amplification of oncogenes cyclin D1 (CCND1),
EGFR, and HER2; non-oncogenes b-actin (ACTB), GUSB, and GAPDH; and
test locus EPOR. The numbers of tumours with amplicons are shown below
the x axis. (B) Per cent of tumours with genomic amplification of genes
from panel A present in amplicons o10Mb plotted against gene copy
numbers. (C) Quantitative genomic PCR analysis of the EPOR locus in 68
breast tumour samples. The EPOR-specific primer/probe sets A and C were
used to amplify EPOR fragments from exons 3 and 8, respectively. Breast
tumour no. 29 had a gain in EPOR copy number (1.6-fold) and no. 50 had a
deletion of one EPOR locus (0.4-fold).
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seffects and promote tumour progression in anaemic cancer
patients (Henke et al, 2003; Leyland-Jones et al, 2005; Bohlius
et al, 2006). The notion that EpoR was overexpressed in tumours
and that rHuEpo enhanced tumour progression has been
confounded by the finding that antibodies used to detect EpoR
are nonspecific and additionally bind non-EpoR proteins, includ-
ing HSP70 (Elliott et al, 2006; Brown et al, 2007; Della Ragione
et al, 2007; Kirkeby et al, 2007; Laugsch et al, 2008; Ragione et al,
2007; Sturiale et al, 2007). Therefore, a recent study suggesting
high-level EpoR expression in head and neck tumours correlated
with tumour progression and worse survival in patients adminis-
tered ESAs (Henke et al, 2006) most likely identified the well-know
association of HSP70 and worse prognosis (Schmitt et al, 2007).
Furthermore, there are a large number of studies that find that
ESAs do not stimulate tumour progression in preclinical models
(reviewed by Osterborg et al, 2007; Sinclair et al, 2007). Since
specific anti-EpoR antibodies have yet to be identified, we
investigated if EpoR was overexpressed in tumours by performing
a systematic analysis of EPOR genomic amplification and
transcription in more than 15 different primary tumour types,
and EpoR transcript and surface EpoR expression analysis in
representative tumour cell lines in which rHuEpo has been
reported to induce responses (Westenfelder and Baranowski,
2000; Acs et al, 2001, 2003; Pajonk et al, 2004; Um et al, 2007).
A common phenomenon of tumour formation is the amplifica-
tion of proto-oncogenes such as HER2 (Parkes et al, 1990), EGFR
(Reissmann et al, 1999), CCND1 (Szepetowski et al, 1992;
Reissmann et al, 1999), and c-MET (Rege-Cambrin et al, 1992),
which provide a selective advantage for tumour cell growth and
survival through overexpression. Genomic analysis of 1083
tumours showed that the EPOR locus was amplified in o0.7%
tumours, only in large amplicons, and less than 2–3 times the
normal copy number. In contrast, EGFR, CCND1, and HER2 were
amplified in 3.5–6.7% of tumours, often 49 times the normal
copy number and frequently amplified in small amplicons
indicative of the selective amplification of these genes. These data
demonstrate that EPOR amplification is a rare event in solid
tumours and not a primary driver of tumour formation and
progression.
Although the EPOR locus was rarely amplified in tumours, it was
possible that EPOR was overexpressed through other mechanisms.
Here, we report the first comprehensive, quantitative analysis of
EPOR transcript levels in multiple tumour types compared to
tissues of tumour origin. In this analysis, we found that levels of
EPOR transcripts in tumour samples and cell lines from more than
15 different tumour types were equivalent to, or lower than, levels
in normal tissues. In concordance with our study, it was recently
reported that levels of EPOR transcripts in prostate (Feldman et al,
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Figure 3 Levels of EPOR transcripts in normal vs tumour tissues. Quantitative RT-PCR was used to determine levels of EPOR transcripts in normal and
tumour tissues relative to levels of cyclophilin B transcripts. (A) Levels of EPOR transcripts in a panel of normal tissues obtained using primer/probe set B
(corroborated with primer/probe set A). EPOR transcript levels relative to cyclophilin were analysed: (B) normal tissues vs tumour tissues and cell lines; (C)
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s2006) and head and neck tumours (Winter et al, 2005) were similar
to levels in normal tissues. High levels of EPOR transcripts were
reported in kidney tumours compared with normal kidney (Lee
et al, 2005) and in melanoma cell lines compared with normal
melanocytes (Selzer et al, 2000). However, these latter studies used
small numbers of samples, and levels of transcripts were not
quantified. In the present study, we examined 11 kidney and 9
melanoma tumour samples and found no increase in levels of
EPOR transcripts relative to normal tissues.
Most solid tumour cell lines we examined expressed EpoR
mRNA; however, the levels were substantially lower compared to
that found in Epo-responsive cells (UT7/Epo) or tissues (bone
marrow). In addition, we were unable to detect EpoR on the cell
surface of the same cells. Owing to non-specificities and
insensitivity of antibodies available for EpoR protein detection
(Elliott et al, 2006; Brown et al, 2007; Della Ragione et al, 2007;
Kirkeby et al, 2007; Laugsch et al, 2008; Sturiale et al, 2007), we
have been unable to determine EpoR protein expression in these
lines. However, the lack of detectable surface binding of
125I-Epo to
intact cells suggests that EpoR protein levels may be low if
expressed at all. Translocation of EpoR to the cell surface is an
inefficient process (less than 1% of total cellular EpoR molecules
are produced on the cell surface); thus, EPOR transcription and
EpoR protein synthesis does not always lead to cell-surface
expression of functional EpoR in tumour cells (Migliaccio et al,
1991; Neumann et al, 1993; Sawyer and Hankins, 1993; Hilton
et al, 1995; Hermine et al, 1996; Kurten et al, 1996; Supino-Rosin
et al, 1999). Thus, an alternative explanation may be inefficient
transport of EpoR protein to the cell surface. Janus kinase 2 is
essential for surface expression of EpoR; in haematopoietic cells, it
binds EpoR in the endoplasmic reticulum, induces correct protein
folding, and localises EpoR to the cell surface (Huang et al, 2001).
Some of the cell lines investigated had no or very low Jak2
expression and may, in part, account for the lack of detectable
EpoR on the surface in some cells if protein is synthesised.
Interestingly, murine 32D-Epo-independent cells expressed Jak2
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Figure 4 Microarray analysis of levels of EPOR transcripts in normal vs
oncogenic samples. Comparative microarray analysis of 121 tumour and
170 normal tissues from breast, colon, kidney, lung, lymph node, ovary,
pancreas, prostate, and skin samples. Closed circles represent transcript
levels from individual samples using EPOR probe 396_F_AT (EPOR exon 8).
Other EPOR probe sets yielded similar intensity profiles. Horizontal,
double-headed arrows indicate no statistical difference in EPOR levels
between normal and tumour tissues. A single-headed arrow indicates a
significant (Po0.05) reduction in levels of EPOR transcripts in tumour
tissues compared with normal tissues. No statistical analyses were
performed on pancreatic samples because of the lack of a normal control,
or on ovary and melanoma samples because of their small sample sizes.
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s(DaSilva et al, 1994) and EpoR, but EpoR was not detected at the
cell surface (Migliaccio et al, 1991). This suggests that accessory
proteins other than Jak2 may also be required to modulate surface
expression of EpoR or may alter the affinity of EpoR for Epo (Dong
and Goldwasser, 1993; Masuda et al, 1993; Nagao et al, 1993;
Hermine et al, 1994). Recently, it has been hypothesised that an
alternative receptor for rHuEpo, a heterodimer of EpoR and the b-
common chain, mediates tissue-protective effects in non-haema-
topoietic tissues (Brines et al, 2004). However, these data were not
reproduced by other investigators (Um et al, 2007). Taken
together, these data suggest that Epo responses in these cells, if
any, may be weak.
It is possible that very low levels of surface receptor on the
tumour cell lines we examined are present and they mediate a
response to rHuEpo, thereby explaining the responses to rHuEpo
reportedly detected by some investigators (Westenfelder and
Baranowski, 2000; Acs et al, 2001, 2003; Um et al, 2007).
Differentiated neuroblastoma cell line SHSY-5Y was reported to
express extremely low (B17) EpoR homodimers on the cell surface
(Um et al, 2007). This level of surface receptor was reportedly
sufficient to induce low-level signalling and survival responses
(Um et al, 2007). A proliferative effect of rHuEpo was reported in
MCF-7 cells (Acs et al, 2001), but seven other studies reported no
proliferative effect in MCF-7 cells (Berdel et al, 1991, 1992; Mundt
et al, 1992; Rosti et al, 1993; Gewirtz et al, 2006; Li et al, 2006;
Laugsch et al, 2008). Also, rHuEpo reportedly increased the
survival of parental HeLa cells in one study (Acs et al, 2003) but
not in another study (Pajonk et al, 2004). Renal carcinoma cell line
CAKI-2 was reported to bind
125I-Epo and proliferate in vitro a
maximum of 2.5-fold (Westenfelder and Baranowski, 2000). Since
most of these studies had technical concerns (e.g., performed in
the absence of serum, lack of critical controls (e.g., vehicle to
control for contaminating carrier proteins), use of suprapharma-
cologic doses of rHuEpo, modest proliferative responses for
established cell lines), the results from these studies are incon-
clusive and inconsistent. In one such study, the direct effect of
rHuEpo to induce signalling and protect a rat mammary
carcinoma cell line from Taxol-induced apoptosis in vitro did
not translate to an effect on Taxol-induced tumour inhibition in
vivo, despite a reported impact on signalling pathways in the
tumour (Hardee et al, 2006). The conclusion that ESAs promote
tumour cell growth is not supported by in vivo studies in rodent
tumour models: in 23 published studies, there was no tumour-
promoting effect of ESAs either alone or in combination with
radiotherapy or chemotherapy (Sinclair et al, 2007). In some
studies, ESAs were reported to enhance the efficiency of tumour-
ablative therapy (Silver and Piver, 1999; Mittelman et al, 2001;
Thews et al, 2001; Golab et al, 2002; Pinel et al, 2004; Sigounas
et al, 2004; Ning et al, 2005) and induce tumour regression
(Mittelman et al, 2001). Therefore, the most physiologically
relevant tumour models that directly examined effects of ESAs
in vivo do not support a tumour-promoting effect of ESAs.
In summary, we found no evidence that EpoR mRNA was
overexpressed in the solid tumour types analysed in this study
(through genomic amplification or other mechanisms). Erythro-
poietin receptor transcript levels were low and EpoR protein was
not trafficked to the cell surface at detectable levels. These data
suggest that primary tumour samples and tumour cell lines did not
overexpress EpoR. Taken together, these results question the
hypothesis that there is functional relevance to EpoR mRNA
transcription in tumours.
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